Q1 2025 Travere Therapeutics Inc Earnings Call Transcript

May 1, 2025 / 08:30 PM GMT

Release Date Price: $20.76 (-0.24%)

Transcript 10-Q

Key Points

Positve

Travere Therapeutics Inc (TVTX) reported a 182% year-over-year growth in net sales, indicating strong demand and uptake for their products.
The company received full approvals for their product in Europe and the UK, expanding their market reach.
Travere Therapeutics Inc (TVTX) completed their NDA submission for an FSGS indication, potentially making their product the first approved medication for this condition.
The company is making progress in their Phase 3 HARMONY study for classical homocystinuria, aiming to restart patient enrollment next year.
Travere Therapeutics Inc (TVTX) maintains a strong financial position with $322.2 million in cash, cash equivalents, and marketable securities, providing flexibility for future investments.

Negative

Despite strong sales growth, Travere Therapeutics Inc (TVTX) reported a net loss of $41.2 million for the first quarter of 2025.
The company anticipates increased generic competition for their products, which could impact future sales.
Higher gross-to-net discounts are expected throughout 2025, potentially affecting profitability.
Travere Therapeutics Inc (TVTX) faces uncertainties related to legislative developments and geopolitical factors that could impact their operations.
The company is still awaiting FDA acceptance of their NDA submission for FSGS, which introduces regulatory risk.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TVTX.OQ - Travere Therapeutics Inc
Q1 2025 Travere Therapeutics Inc Earnings Call
May 01, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
I mean and in and in and we do, yes, back in and in June in Europe contributing in a minute.

Thanks, good afternoon, and welcome to the KVH Therapeutics First Quarter 2025 financial results conference call.

Today's call is being recorded.

At this time, I would like to turn the conference call over to Victoria Prescott, Manager of Investor Relations.

Please go ahead.

Victoria.

Thank you, Paul, and good afternoon, and welcome to trivia Therapeutics First Quarter 2025 Financial Results and Corporate Update Call.

Thank you all for joining today's call will be led by Eric Newby, our President and Chief Executive Officer.

Eric will be joined in the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.